Wells Fargo & Company Soligenix, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.4 - $168.0 $492 - $206,808	1,231 Added 430.42%	1,517 $0
Q3 2022 Nov 14, 2022	SELL	$0.51 - $117.79 $511 - $118,025	-1,002 Reduced 77.8%	286 $0
Q2 2022 Aug 12, 2022	SELL	$0.4 - $0.75 $1,190 - $2,232	-2,976 Reduced 69.79%	1,288 $1,000
Q1 2022 May 16, 2022	BUY	$0.61 - $0.75 $10 - $13	18 Added 0.42%	4,264 $3,000
Q3 2021 Nov 15, 2021	BUY	$0.9 - $1.31 $889 - $1,294	988 Added 30.33%	4,246 $4,000
Q2 2021 Aug 16, 2021	BUY	$0.87 - $1.58 $46 - $85	54 Added 1.69%	3,258 $3,000
Q1 2021 May 13, 2021	BUY	$1.31 - $2.35 $13 - $23	10 Added 0.31%	3,204 $5,000
Q4 2020 Feb 09, 2021	SELL	$1.26 - $2.75 $1,246 - $2,719	-989 Reduced 23.64%	3,194 $4,000
Q3 2020 Nov 05, 2020	SELL	$1.7 - $2.61 $2,420 - $3,716	-1,424 Reduced 25.4%	4,183 $7,000
Q2 2020 Aug 13, 2020	BUY	$1.36 - $2.26 $4,081 - $6,782	3,001 Added 115.16%	5,607 $12,000
Q1 2020 May 14, 2020	BUY	$1.42 - $3.34 $3,700 - $8,704	2,606 New	2,606 $4,000

Ticker SNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,105,200
Market Cap $124M
Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has c...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.